Association between the expression levels of tumor necrosis factor-α-induced protein 8 and the prognosis of patients with gastric adenocarcinoma

Chen,Ling; Yang,Xigui; Yang,Xiangshan; Fan,Kaixi; Xiao,Ping; Zhang,Jing; Wang,Xiuwen

doi:10.3892/etm.2016.3327

Association between the expression levels of tumor necrosis factor-α-induced protein 8 and the prognosis of patients with gastric adenocarcinoma

Authors:
- Ling Chen
- Xigui Yang
- Xiangshan Yang
- Kaixi Fan
- Ping Xiao
- Jing Zhang
- Xiuwen Wang
View Affiliations

Affiliations: Department of Medical Oncology, Cancer Center, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China, Department of Internal Medicine‑Oncology, Affiliated Hospital of Shandong Academy of Medical Sciences, Jinan, Shandong 250031, P.R. China, Department of Pathology, Affiliated Hospital of Shandong Academy of Medical Sciences, Jinan, Shandong 250031, P.R. China
Published online on: May 10, 2016 https://doi.org/10.3892/etm.2016.3327
Pages: 238-244
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the expression levels of tumor necrosis factor-α-induced protein 8 (TNFAIP8) in gastric adenocarcinoma. TNFAIP8 expression levels in gastric adenocarcinoma tissue samples (with and without lymph node metastasis), adjacent normal tissue samples and metastatic lymph node tissue samples were detected by immunohistochemistry. The correlation between TNFAIP8 expression levels and clinicopathological data and gastric adenocarcinoma prognosis was analyzed. The results demonstrated that TNFAIP8 expression in gastric adenocarcinoma tissue samples and metastatic lymph node tissue samples markedly increased at a rate of 47.2% (50/106) and 81.7% (49/60), respectively, as compared with the adjacent normal tissue samples in which no TNGFAIP8 expression was detected (0%). This increase in TNFAIP8 expression was statistically significant. TNFAIP8 expression rates in the primary tumors (60%, 36/60) of patients with lymph node metastasis were significantly higher compared with the primary tumors of patients without lymph node metastasis (30.4%, 14/46). TNFAIP8 expression was associated with an increase in the severity of TNM stage, tumor grade, vascular invasion, lymph node metastasis and serum CA72‑4 levels. The overall survival rate of patients with gastric adenocarcinoma and high TNFAIP8 expression was poorer compared with patients with low TNFAIP8 expression, and TNFAIP8 expression was negatively correlated with patient prognosis. The results also demonstrated that TNFAIP8 was an independent prognostic marker in gastric adenocarcinoma (relative risk, 1.736; P=0.029). In conclusion, the results of the present study demonstrated that TNFAIP8 expression was associated with the occurrence, development and metastasis of gastric adenocarcinoma, and negatively correlated with the prognosis of patients with gastric adenocarcinoma. TNFAIP8 may therefore serve as a prognostic factor for gastric adenocarcinoma.

View Figures

View References

1	American Cancer Society: Global cancer facts and figures (2nd). Atlanta, USA: 19–20. 2011.
2	Compare D, Rocco A and Nardone G: Risk factors in gastric cancer. Eur Rev Med Pharmacol Sci. 14:302–308. 2010.PubMed/NCBI
3	Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol. 2:533–543. 2001. View Article : Google Scholar : PubMed/NCBI
4	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
5	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
6	Chen J, Rocken C, Malfertheiner P and Ebert MP: Recent advances in molecular diagnosis and therapy of gastric cancer. Dig Dis. 22:380–385. 2004. View Article : Google Scholar : PubMed/NCBI
7	Blaser MJ and Atherton JC: Helicobacter pylori persistence: Biology and disease. J Clin Invest. 113:321–333. 2004. View Article : Google Scholar : PubMed/NCBI
8	Zhang Y, Sun LP, Xing CZ, Xu Q, He CY, Li P, Gong YH, Liu YP and Yuan Y: Interaction between GSTP1 Val allele and H. pylori infection, smoking and alcohol consumption and risk of gastric cancer among the Chinese population. PLoS One. 7:e471782012. View Article : Google Scholar : PubMed/NCBI
9	Kim J, Cho YA, Choi IJ, Lee YS, Kim SY, Shin A, Cho SJ, Kook MC, Nam JH, Ryu KW, et al: Effects of interleukin-10 polymorphisms, Helicobacter pylori infection and smoking on the risk if noncardia gastric cancer. PLoS One. 7:e296432012. View Article : Google Scholar : PubMed/NCBI
10	Fukuda H, Saito D, Hayashi S, Hisai H, Ono H, Yoshida S, Oguro Y, Noda T, Sato T, Katoh M, et al: Helicobacter pylori infection, serum pepsinogen level and gastric cancer: A case-control study in Japan. Jpn J Cancer Res. 86:64–71. 1995. View Article : Google Scholar : PubMed/NCBI
11	Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, Yoshikawa A, Yanaoka K, Arii K, Tamai H, et al: Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer. 109:138–143. 2004. View Article : Google Scholar : PubMed/NCBI
12	Oishi Y, Kiyohara Y, Kubo M, Tanaka K, Tanizaki Y, Ninomiya T, Doi Y, Shikata K, Yonemoto K, Shirota T, et al: The serum pepsinogen test as a predictor of gastric cancer: The Hisayama study. Am J Epidemiol. 163:629–637. 2006. View Article : Google Scholar : PubMed/NCBI
13	Ren JS, Kamangar F, Qiao YL, Taylor PR, Liang H, Dawsey SM, Liu B, Fan JH and Abnet CC: Serum pepsinogens and risk of gastric and oesophageal cancers in the general population nutrition intervention trial cohort. Gut. 58:636–642. 2009. View Article : Google Scholar : PubMed/NCBI
14	Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, Doi H, Yoshida H, Kawabe T and Omata M: Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: A prospective endoscopic cohort study. Gut. 54:764–768. 2005. View Article : Google Scholar : PubMed/NCBI
15	Ye W, Held M, Lagergren J, Engstrand L, Blot WJ, McLaughlin JK and Nyrén O: Helicobacter pylori infection and gastric atrophy: Risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst. 96:388–396. 2004. View Article : Google Scholar : PubMed/NCBI
16	You WC, Blot WJ, Zhang L, Kneller RW, Li JY, Jin ML, Chang YS, Zeng XR, Zhao L, Fraumeni JF Jr, et al: Serum pepsinogens in relation to precancerous gastric lesions in a population at high risk for gastric cancer. Cancer Epidemiol Biomarkers Prev. 2:113–117. 1993.PubMed/NCBI
17	Correa P: A human model of gastric carcinogenesis. Cancer Res. 48:3554–3560. 1988.PubMed/NCBI
18	Zhang M, Wang X, Li W and Cui Y: miR-107 and miR-25 simultaneously target LATS2 and regulate proliferation and invasion of gastric adenocarcinoma (GAC) cells. Biochem Biophys Res Commun. 460:806–812. 2015. View Article : Google Scholar : PubMed/NCBI
19	Song YX, Zhou X, Wang ZN, Gao P, Li AL, Liang JW, Zhu JL, Xu YY and Xu HM: The association between individual SNPs or haplotypes of matrix metalloproteinase 1 and gastric cancer susceptibility, progression and prognosis. PLoS One. 7:e380022012. View Article : Google Scholar : PubMed/NCBI
20	Ajani JA, Barthel BJ and Bekall-Saab T: NCCN Clinical practice guidelines in oncology, gastric cancer. v.1.2011. Washington: National Comprehensive Cancer Network 26. 2011.
21	Saif MW, Makrilia N, Zalonis A, Merikas M and Syrigos K: Gastric cancer in the elderly: An overview. Eur J Surg Oncol. 36:709–717. 2010. View Article : Google Scholar : PubMed/NCBI
22	Brenner H, Rothenbacher D and Arndt V: Epidemiology of stomach cancer. Methods Mol Biol. 472:467–477. 2009. View Article : Google Scholar : PubMed/NCBI
23	Patel S, Wang FH, Whiteside TL and Kasid U: Identification of seven differentially displayed transcripts in human primary and matched metastatic head and neck squamous cell carcinoma cell lines: Implications in metastasis and/or radiation response. Oral Oncol. 33:197–203. 1997. View Article : Google Scholar : PubMed/NCBI
24	Kumar D, Whiteside TL and Kasid U: Identification of a novel tumor necrosis factor-alpha-inducible gene, SCC-S2, containing the consensus sequence of a death effector domain of fas-associated death domain-like interleukin-1 beta-converting enzyme-inhibitory protein. J Biol Chem. 275:2973–2978. 2000. View Article : Google Scholar : PubMed/NCBI
25	You Z, Quyang H, Lopatin D, Polver PJ and Wang CY: Nuclear factor-kappa B-inducible death effector domain-containing protein suppresses tumor necrosis factor-mediated apoptosis by inhibiting caspase-8 activity. J Biol Chem. 276:26398–26404. 2001. View Article : Google Scholar : PubMed/NCBI
26	Freundt EC, Bidere N and Lenardo MJ: A different TIPE of immune homeostasis. Cell. 133:401–402. 2008. View Article : Google Scholar : PubMed/NCBI
27	Sun H, Gong S, Carmody RJ, Hilliard A, Li L, Sun J, Kong L, Xu L, Hilliard B, Hu S, et al: TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell. 133:415–426. 2008. View Article : Google Scholar : PubMed/NCBI
28	Zhang C, Chakravarty D, Sakabe I, Mewani RR, Boudreau HE, Kumar D, Ahmad I and Kasid UN: Role of SCC-S2 in experimental metastasis and modulation of VEGFR-2, MMP-1 and MMP-9 expression. Mol Ther. 13:947–955. 2006. View Article : Google Scholar : PubMed/NCBI
29	Miao Z, Zhao T, Wang Z, Xu Y, Song Y, Wu J and Xu H: SCC-S2 is overexpressed in colon cancers and regulates cell proliferation. Tumour Biol. 33:2099–2106. 2012. View Article : Google Scholar : PubMed/NCBI
30	Zhang C, Kallakury BV, Ross JS, Mewani RR, Sheehan CE, Sakabe I, Luta G, Kumar D, Yadavalli S, Starr J, et al: The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence. Int J Cancer. 133:31–42. 2013. View Article : Google Scholar : PubMed/NCBI
31	Hadisaputri YE, Miyazaki T, Suzuki S, Yokobori T, Kobayashi T, Tanaka N, Inose T, Sohda M and Kuwano H: TNFAIP8 overexpression: Clinical relevance to Esophageal squamous cell carcinoma. Ann Surg Oncol. 19(Suppl 3): S589–S596. 2012. View Article : Google Scholar : PubMed/NCBI
32	Shi TY, Cheng X, Yu KD, Sun MH, Shao ZM, Wang MY, Zhu ML, He J, Li QX, Chen XJ, et al: Functional variants in TNFAIP8 associated with cervical cancer susceptibility and clinical outcomes. Carcinogenesis. 34:770–778. 2013. View Article : Google Scholar : PubMed/NCBI
33	Dong QZ, Zhao Y, Liu Y, Wang Y, Zhang PX, Jiang GY, Dong XJ, Cui QZ and Wang EH: Overexpression of SCC-S2 correlates with lymph node metastasis and poor prognosis in patients with non-small-cell lung cancer. Cancer Sci. 101:1562–1569. 2010. View Article : Google Scholar : PubMed/NCBI
34	Liu K, Qin CK, Wang ZY, Liu SX, Cui XP and Zhang DY: Expression of tumor necrosis factor-alpha-induced protein 8 in pancreas tissues and its correlation with epithelial growth factor receptor levels. Asian Pac J Cancer Prev. 13:847–850. 2012. View Article : Google Scholar : PubMed/NCBI
35	Liu T, Gao H, Chen X, Lou G, Gu L, Yang M, Xia B and Yin H: TNFAIP8 as a predictor of metastasis and a novel prognostic biomarker in patients with epithelial ovarian cancer. Br J Cancer. 109:1685–1692. 2013. View Article : Google Scholar : PubMed/NCBI
36	Liu T, Gao H, Yang M, Zhao T, Liu Y and Lou G: Correlation of TNFAIP8 overexpression with the proliferation, metastasis and disease-free survival in endometrial cancer. Tumour Biol. 35:5805–5814. 2014. View Article : Google Scholar : PubMed/NCBI
37	Kumar D, Gokhale P, Broustas C, Chakravarty D, Ahmad I and Kasid U: Expression of SCC-S2, an antiapoptotic molecule, correlates with enhanced proliferation and tumorigenicity of MDA-MB 435 cells. Oncogene. 23:612–616. 2004. View Article : Google Scholar : PubMed/NCBI
38	Hamilton SR and Aaltonen LA: Pathology and genetics of tumours of the digestive system. World Health Organization Classification of Tumours (Lyon, France). IARC Press. 38–52. 2000.
39	Stephen EB, David BR, Carolyn CC, April GF, Frederick LG and Andy T: AJCC cancer staging manual (7th). Lippincott-Raven. Philadelphia, PA: 2010:117–127. 2010.
40	Klein JP and Moeschberger ML: Survival analysis: Techniques for censored and truncated data. Springer. New York: 83–109. 2003.
41	Romanuik TL, Ueda T, Le N, Haile S, Yong TM, Thomson T, Vessella RL and Sadar MD: Novel biomarkers for prostate cancer including noncoding transcripts. Am J Pathol. 175:2264–2276. 2009. View Article : Google Scholar : PubMed/NCBI
42	Jacobs JJ, Lehe C, Cammans KD, Yoneda K, Das PK and Elliott GR: An automated method for the quantification of immunostained human Langerhans cells. J Immunol Method. 247:73–82. 2001. View Article : Google Scholar
43	Wen Q, Liao HF, Yuan SB, Qiu XF, Zhuang GH and Liu ZC: Expression and clinical significance of TNFAIP8 in gastric tissues. Mian Yi Xue Za Zhi. 02:181–184. 2012.(In Chinese).
44	Byrne DJ, Browning MC and Cuschieri A: CA72-4: A new tumor marker for gastric cancer. Br J Surg. 77:1010–1013. 1990. View Article : Google Scholar : PubMed/NCBI
45	Hamazoe R, Maeta M, Matsui T, Shibata S, Shiota S and Kaibara N: CA72-4 compared with carcinoembryonic antigen as a tumor marker for gastric cancer. Eur J Cancer. 28A:1351–1354. 1992. View Article : Google Scholar : PubMed/NCBI
46	Ikeguchi M, Katano K, Saitou H, Tsujitani S, Maeta M and Kaibara N: Pre-operative serum levels of CA72-4 in patients with gastric adenocarcinoma. Hepatogastroenterology. 44:866–871. 1997.PubMed/NCBI
47	Sougioultzis S, Syrios J, Xynos ID, Bovaretos N, Kosmas C, Sarantonis J, Dokou A, Tzivras D, Zografos G, Felekouras E, et al: Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemotherapy: A retrospective analysis. Eur J Surg Oncol. 37:312–318. 2011. View Article : Google Scholar : PubMed/NCBI